Novartis Ag

Novartis Pharma Gmbh

David Beattie

Ian Bruce

Bernard Cuenoud

Robin Alec Fairhurst

David Andrew Sandham

Andrew James Culshaw

Urs Baettig

Simon James Watson

Jeffrey McKenna

Christopher Thomson

Emily Stanley

Oliver Ross Steward

David William Pearce

Anny-Odile Colson

Andrew Stuart Lister

Roger John Taylor

Neil John Press

Darren Mark Le Grand

Darren Mark Legrand

Thomas Hugo Keller

Lisa Ann Rooney

Katharine Louise Turner

Christopher G Thomson

Lilya Sviridenko

Gaynor Elizabeth Pilgrim

Thomas Sharp

Lisa Sharp

Reamonn Madden

Jeffrey Mckenna

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Autotaxin inhibitors

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin. 

Compounds of formula in free or salt or solvate form, whereAr is a group of formula Y is carbon or nitrogen and R, R, R, R, R, R, R, R, R, R, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

BETA2-adrenoceptor agonists

There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists Formula (I). 

Cyclohexyl amide derivatives as CRF receptor antagonists

Beta2-adrenoreceptor agonists

Compounds of formula in free or salt or solvate form, where 

BETA2-adrenoreceptor agonists

There are described cyclohexyl amide derivatives useful as corticotropin releasing (CRF) receptor antagonists.

Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists

Compounds of formula in free or salt or solvate form, where Ar is a group of formula  Y is carbon or nitrogen and R, R, R, R, R, R, R, R, R, R, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Beta-2-adrenoreceptor agonists

There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists.

Organic compounds

Compounds of formula I in free or salt form, wherein &#x2014;C&#x2014;Y&#x2014;, Rand Rare G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the &#x3b2;-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Quinoline-2-one derivatives for the treatment of airways diseases

&#x3b2;2-adrenoceptor agonists

Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals

Growing community of inventors

Horsham, United Kingdom

David Beattie